Obinutuzumab beta

奥妥珠单抗β

Report date: 2026/03/16 20:01:47

Base Information

Drug NameObinutuzumab beta
Drug Alias Name重组人源化单克隆抗体MIL62Recombinant humanized monoclonal antibody MIL62重组人源化单抗MIL62Obinutuzumab β倍捷欣 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLupus Erythematosus, SystemicNephrosisLupus Nephritis +[9] 
Global Approved IndicationsNeuromyelitis Optica
Approved Indications in ChinaNeuromyelitis Optica
Original Approved Country/TerritoryMainland China
Original Approved Date2026/02/10
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Innocare Pharma Tech Co LtdBeijing Mabworks Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Huafang Tianshi Biopharmaceutical Co LtdBeijing Mabworks Biotech Co LtdJiangsu Hengrui Pharmaceutical Group Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicNephrosisLupus Nephritis +[8] 
Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A